Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Autoimmune hepatitis (AIH) is very frequently associated with many autoimmune diseases. Antiphospholipid syndrome (APS) is frequently associated with type 1 AIH but rarely seen in type 2 AIH patients. In this case, the association between type 2 AIH and APS is seen, along with complications, which made the management difficult.

Case Presentation: This patient, who had a history of recurrent abortions, presented with complaints of recurrent epistaxis with severe thrombocytopenia. She was diagnosed with APS with concomitant type 2 AIH. After failing with conservative treatment, partial splenic artery embolization (PSAE) for recurrent thrombocytopenia was done, which led to improvement in platelet count and the resolution of recurrent epistaxis. But after a few days, the patient developed an intracranial hemorrhage (ICH) with a normal platelet count and coagulation profile. A platelet function study was done, and platelet dysfunction was found. Finally, after a prolonged period of admission, the patient developed sepsis and disseminated intravascular coagulation (DIC) and succumbed to death.

Conclusion: From this case, it may be kept in mind the possibility of the association of both types of AIH when dealing with a patient with APS. Unconventional methods such as partial splenic artery embolization can be useful in patients with recurrent thrombocytopenia. A platelet function study is a very important parameter to look for whenever a patient has bleeding with a normal coagulation profile and platelet count with isolated raised activated partial thromboplastin time (aPTT).

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12226965PMC
http://dx.doi.org/10.7759/cureus.85337DOI Listing

Publication Analysis

Top Keywords

type aih
16
platelet count
12
autoimmune hepatitis
8
antiphospholipid syndrome
8
intracranial hemorrhage
8
frequently associated
8
recurrent epistaxis
8
partial splenic
8
splenic artery
8
artery embolization
8

Similar Publications

Hepatitis A virus (HAV) typically causes a self-limiting illness in children. Rarely, it can progress to fulminant hepatic failure (FHF), and even less commonly, may be followed by features suggestive of autoimmune hepatitis (AIH). The diagnostic overlap can be particularly challenging in tropical regions, where endemic infections such as dengue and malaria may present with similar clinical features.

View Article and Find Full Text PDF

Background: Multiple myeloma (MM) is a common malignant tumor of the hematological system caused by the malignant proliferation of plasma cells, characterized by the production of M proteins and CRAB symptoms. Among them, the Immunoglobulin G MM is the most common, while the IgG4-MM is extremely rare. Smoldering multiple myeloma refers to a state where there are no clinical symptoms.

View Article and Find Full Text PDF

Genetic evidence for causal links between type 1 diabetes and autoimmune liver diseases.

Diabetol Metab Syndr

August 2025

Department of General Surgery, University-Town Hospital of Chongqing Medical University, No. 55, University Town Middle Road, Shapingba District, Chongqing, 400000, China.

Background: Type 1 diabetes (T1D) and autoimmune liver diseases (AILDs), including autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC), are characterized by immune-mediated damage. Prior observational studies have reported associations between these conditions, but definitive causal relationships remain elusive. This study leverages genetic data to clarify the nature of these associations.

View Article and Find Full Text PDF

Autoimmune hepatitis (AIH) is a special type of chronic liver disease caused by immune dysfunction in the body. This study aims to explore the molecular regulatory mechanisms of inflammation and fibrosis in AIH. Bioinformatics was used to screen differentially expressed genes in autoimmune hepatitis and reveal core gene functions.

View Article and Find Full Text PDF

Background: No therapy is approved for patients with symptomatic nonobstructive hypertrophic cardiomyopathy (nHCM). The ODYSSEY-HCM (A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy [ODYSSEY-HCM]; NCT05582395) trial, the largest to date in patients with hypertrophic cardiomyopathy (HCM), evaluating the efficacy of mavacamten in symptomatic adults with nHCM, did not demonstrate improvements in its primary endpoints (functional capacity and patient-reported health status).

Objectives: The current exploratory analysis from the ODYSSEY-HCM trial reports the associations between: 1) baseline biomarkers (N-terminal pro-B-type natriuretic peptide [NT-proBNP] and high-sensitivity cardiac troponin I [cTnI]) with clinical, exercise, and echocardiographic characteristics; and 2) comparing changes in these biomarkers from baseline to week 48 between mavacamten and placebo groups.

View Article and Find Full Text PDF